

420-4-1-.04 Reporting.

(2) Reports by Pharmacists. Any pharmacist dispensing anti-tuberculosis medication shall report this information to the State Health Officer, to the County Health Officer or their designee in the manner designated in Rule 420-4-1-.04(3)(4)(5).

(3) Report of Group A Diseases. Diseases designated as Group A shall be reported to the State Health Officer or the County Health Officer within twenty-four (24) hours of diagnosis by telephone, telegraph, or in person. Said report shall contain as a minimum the name of the disease or health condition, the name and the address of the person having the disease or health condition, the date of onset and/or date of diagnosis of said disease or health condition.

(4) Report of Group B Diseases. Group B diseases notifiable within seven (7) days. Diseases and health conditions designated as Group B diseases shall require notification in writing to either the County Health Officer or the State Health Officer within seven (7) days. Said report shall include at a minimum the name of the disease or health condition, the name and the address of the person having said disease or health condition, the date of onset and/or date of diagnosis of said disease or health condition.

(5) Notification of suspected presence of *Bacillus anthracis* or other agent suspected to be related to an act of bioterrorism. All hospital laboratories, independent clinical laboratories, laboratories in rehabilitation hospitals or ambulatory surgical centers and any other clinical laboratories licensed by the State Board of Health and all physicians or other practitioners operating in-office laboratories shall immediately notify the State Board of Health in the manner specified below of the existence of and forward a sample of any of the following to the Alabama Department of Public Health, Bureau of Clinical Laboratories:

(a) isolates or suspected isolates of *Bacillus anthracis* regardless of clinical source;

(b) isolates of all bacillus species obtained from normally sterile clinical sites including, but not limited to cerebral spinal fluid, blood, pleural fluid; or

(c) clinical or environmental isolates of any organism suspected of being related to an act of bioterrorism.

Manner of notification. Such laboratories shall immediately telephone the director of the Bureau of Clinical Laboratories or designee in Montgomery at 334.260.3400 to report such and shall follow the directions of the laboratory director or designee for the transportation of the sample to the state laboratory.